GO:0046890 regulation of lipid biosynthetic process: Lipogenesis Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0046890 (regulation of lipid biosynthetic process) encompasses any process that modulates the frequency, rate or extent of lipid formation, including de novo lipogenesis (DNL).
• Key transcription factors such as SREBP1, PPARγ, and ATF3 integrate hormonal and metabolic signals to control lipid biosynthetic gene expression.
• Dysregulation of this process contributes to metabolic dysfunction-associated steatohepatitis (MASH), hepatocellular carcinoma, and ferroptosis resistance in cancer.
• Signaling pathways including PI3K-AKT-mTOR and CD36-INSIG2-SREBP1 are central upstream regulators of lipid biosynthesis.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of regulatory nodes in lipid biosynthesis.
• Understanding GO:0046890 offers therapeutic opportunities for metabolic diseases and cancers by targeting lipogenic enzymes and their regulators.
Description
The regulation of lipid biosynthetic process (GO:0046890) is a fundamental biological process that controls the production of lipids, including fatty acids, triglycerides, phospholipids, and sterols. This process is essential for energy storage, membrane biogenesis, and signaling molecule synthesis. De novo lipogenesis (DNL) converts excess carbohydrates into fatty acids and is tightly regulated at transcriptional and post-translational levels. Dysregulation of lipid biosynthesis is a hallmark of metabolic disorders such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD), as well as various cancers. Recent studies have highlighted the role of key transcription factors like SREBP1, PPARγ, and ATF3 in modulating lipogenic gene expression in response to metabolic cues. Understanding the molecular mechanisms governing GO:0046890 is therefore critical for developing targeted therapies for these diseases. This article synthesizes current knowledge from authoritative QuickGO annotations and verified PubMed literature to provide a comprehensive overview of the regulation of lipid biosynthetic process, its key genes, disease implications, and research methodologies.
regulation of lipid biosynthetic process At A Glance
| GO ID | GO:0046890 |
|---|---|
| GO term | regulation of lipid biosynthetic process |
| Ontology | biological_process |
| Synonym | regulation of lipid anabolism, regulation of lipid biosynthesis, regulation of lipid formation, regulation of lipid synthesis, regulation of lipogenesis |
| Major function | Modulates the frequency, rate or extent of lipid formation, including de novo lipogenesis and lipid anabolism |
| Key regulators | SREBP1, PPARγ, ATF3, CD36, INSIG2, USP22, PI3K-AKT-mTOR pathway |
| Associated diseases | Metabolic dysfunction-associated steatohepatitis (MASH), hepatocellular carcinoma, ferroptosis resistance, obesity, type 2 diabetes |
| Research methods | CRISPR knockout/knock-in, RNA-seq, ChIP-seq, lipidomics, metabolic flux analysis |
What Is GO:0046890?
According to the Gene Ontology, GO:0046890 (regulation of lipid biosynthetic process) is defined as any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids. This includes the regulation of lipid anabolism, biosynthesis, formation, synthesis, and lipogenesis. It encompasses both positive and negative regulation of the enzymatic steps that convert precursors such as acetyl-CoA into fatty acids, triglycerides, and other lipid molecules.
Why Is regulation of lipid biosynthetic process Important in Cell Biology?
The regulation of lipid biosynthetic process is crucial for maintaining cellular energy homeostasis and membrane integrity. Its dysregulation is directly linked to prevalent human diseases, including metabolic syndrome, fatty liver disease, and cancer. For instance, oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis, promoting tumor survival. In hepatocytes, CD36 promotes de novo lipogenesis through INSIG2-dependent SREBP1 processing, contributing to steatosis. Moreover, ATF3-mediated metabolic reprogramming in hepatic macrophages orchestrates metabolic dysfunction-associated steatohepatitis. Therefore, deciphering the regulatory mechanisms of GO:0046890 is essential for identifying therapeutic targets and biomarkers for these conditions.
• Controls energy storage and mobilization in adipose tissue.
• Supports membrane biogenesis and cell proliferation in cancer.
• Regulates macrophage reparative functions during tissue repair.
• Contributes to the pathogenesis of metabolic dysfunction-associated steatohepatitis (MASH).
• Modulates ferroptosis sensitivity in cancer cells.
• Influences hepatocellular carcinoma progression via USP22-mediated PPARγ stabilization.
• Integrates hormonal and nutritional signals through mTOR and insulin pathways.
• Provides targets for therapeutic intervention in obesity and diabetes.
• Affects intestinal L-cell mechanoreception and hepatic lipid metabolism via GLP-1.
• Serves as a model for studying gene-environment interactions in metabolic diseases.
What Happens During regulation of lipid biosynthetic process?
Transcriptional Control of Lipogenic Genes
In simple terms: The cell decides how much fat to make by turning specific genes on or off.
The regulation of lipid biosynthetic process begins with transcriptional control of genes encoding lipogenic enzymes such as fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and stearoyl-CoA desaturase (SCD). Key transcription factors, including sterol regulatory element-binding protein 1 (SREBP1) and peroxisome proliferator-activated receptor gamma (PPARγ), bind to promoters of these genes to activate their expression in response to insulin, nutrients, or growth factors. For example, SREBP1 is activated by PI3K-AKT-mTOR signaling, which promotes lipogenesis and suppresses ferroptosis in cancer cells. PPARγ T166 dephosphorylation triggers lipid synthesis that sustains reparative function of macrophages during tissue repair.
Post-translational Regulation of Lipogenic Enzymes
In simple terms: Even after genes are turned on, the resulting proteins can be modified to change their activity.
Lipogenic enzymes and their regulators undergo post-translational modifications that fine-tune lipid biosynthesis. For instance, CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing, which involves proteolytic cleavage and nuclear translocation of SREBP1. Additionally, USP22 stabilizes PPARγ by deubiquitination, leading to enhanced lipid accumulation in hepatocellular carcinoma. These modifications allow rapid adaptation to changing metabolic demands.
Signaling Pathways Integrating Metabolic Cues
In simple terms: Hormones and nutrients send signals that tell the cell whether to make more or less fat.
The regulation of lipid biosynthetic process is integrated by signaling pathways such as PI3K-AKT-mTOR, which senses growth factors and amino acids to promote lipogenesis. Insulin signaling activates SREBP1 and PPARγ, while AMPK inhibits lipogenesis under low-energy conditions. ATF3, a stress-inducible transcription factor, mediates metabolic reprogramming in hepatic macrophages, orchestrating MASH progression. Furthermore, intestinal L-cell mechanoreception regulates hepatic lipid metabolism through GLP-1, highlighting inter-organ communication.
Feedback and Homeostatic Control
In simple terms: The cell monitors lipid levels and adjusts production to avoid excess or deficiency.
Feedback mechanisms maintain lipid homeostasis by sensing sterol and fatty acid levels. For example, INSIG2 retains SREBP1 in the endoplasmic reticulum when sterols are abundant, preventing overproduction. Conversely, low sterol levels trigger SREBP1 processing and activation. Dysregulation of these feedback loops leads to pathological lipid accumulation, as seen in MASH and cancer.
Key Genes Involved in GO:0046890 regulation of lipid biosynthetic process
The following genes and proteins are central to the regulation of lipid biosynthetic process (GO:0046890), as supported by verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SREBP1 | Master transcription factor activating lipogenic genes | Central regulator of de novo lipogenesis; target in cancer and fatty liver disease |
| PPARγ | Nuclear receptor promoting lipid synthesis and storage | Modulates macrophage reparative function and hepatocellular carcinoma lipid accumulation |
| ATF3 | Stress-inducible transcription factor | Mediates metabolic reprogramming in hepatic macrophages during MASH |
| CD36 | Fatty acid translocase | Promotes de novo lipogenesis via INSIG2-dependent SREBP1 processing |
| INSIG2 | ER membrane protein retaining SREBP1 | Regulates SREBP1 processing and lipid synthesis feedback |
| USP22 | Deubiquitinase stabilizing PPARγ | Enhances lipidome accumulation in hepatocellular carcinoma |
| PI3K | Kinase activating AKT | Oncogenic signaling suppresses ferroptosis via SREBP-mediated lipogenesis |
| AKT | Serine/threonine kinase | Activates mTOR and downstream lipogenic transcription |
| mTOR | Kinase integrating nutrient and growth signals | Promotes lipogenesis through SREBP1 activation |
| FASN | Fatty acid synthase enzyme | Catalyzes de novo fatty acid synthesis; target for metabolic diseases |
| ACC | Acetyl-CoA carboxylase | Rate-limiting enzyme in fatty acid synthesis |
| SCD | Stearoyl-CoA desaturase | Introduces double bonds in fatty acids; regulated by SREBP1 |
| GLP-1 | Incretin hormone | Mediates intestinal L-cell mechanoreception to regulate hepatic lipid metabolism |
| LXR | Liver X receptor | Regulates cholesterol and fatty acid synthesis |
| ChREBP | Carbohydrate-responsive element-binding protein | Activates lipogenic genes in response to glucose |
| AMPK | AMP-activated protein kinase | Inhibits lipogenesis under low-energy conditions |
| HNF4α | Hepatocyte nuclear factor 4 alpha | Regulates lipid homeostasis in liver |
How Is regulation of lipid biosynthetic process Regulated?
The regulation of lipid biosynthetic process is controlled at multiple levels. Transcriptional regulation by SREBP1, PPARγ, and ChREBP responds to insulin, glucose, and growth factors. Post-translational modifications, such as phosphorylation and ubiquitination, modulate the stability and activity of these factors; for example, PPARγ T166 dephosphorylation triggers lipid synthesis in macrophages, and USP22 stabilizes PPARγ in hepatocellular carcinoma. Signaling pathways including PI3K-AKT-mTOR and AMPK integrate nutrient and energy status to either promote or inhibit lipogenesis. Additionally, inter-organ communication via GLP-1 from intestinal L-cells regulates hepatic lipid metabolism. Feedback inhibition by sterols through INSIG2 ensures homeostatic control.
regulation of lipid biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ATF3 | Metabolic dysfunction-associated steatohepatitis (MASH) | Liver-specific Atf3 knockout mice |
| SREBP1 | Ferroptosis resistance in cancer | SREBP1 knockout cancer cell lines |
| PPARγ | Hepatocellular carcinoma | PPARγ T166 point mutation knock-in mice |
| CD36 | Hepatic steatosis | CD36 overexpression in hepatocytes |
| USP22 | Hepatocellular carcinoma | USP22 knockout HCC xenografts |
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Dysregulation of lipid biosynthesis contributes to the accumulation of triglycerides in hepatocytes, leading to steatosis and MASH. ATF3-mediated metabolic reprogramming in hepatic macrophages orchestrates MASH progression by modulating lipid handling and inflammation. CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing, exacerbating hepatic steatosis. Targeting these pathways may offer therapeutic strategies for MASH.
Hepatocellular Carcinoma (HCC)
Enhanced lipid biosynthesis supports rapid cancer cell proliferation and survival. USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma, promoting tumor growth. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis, contributing to cancer cell survival. Inhibiting lipogenesis or inducing ferroptosis may be effective in HCC treatment.
Ferroptosis Resistance in Cancer
Ferroptosis is an iron-dependent form of cell death characterized by lipid peroxidation. Activation of PI3K-AKT-mTOR signaling suppresses ferroptosis by upregulating SREBP-mediated lipogenesis, which alters lipid composition and reduces susceptibility to ferroptosis. This mechanism represents a target for overcoming therapy resistance in cancers with activated PI3K-AKT-mTOR.
Obesity and Type 2 Diabetes
De novo lipogenesis in adipose tissue and liver is tightly linked to obesity and insulin resistance. Excessive lipid synthesis contributes to adipose tissue expansion and ectopic fat deposition, impairing insulin sensitivity. Understanding the regulation of lipid biosynthetic process is essential for developing interventions for these metabolic disorders.
From regulation of lipid biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SREBP1 reduce lipogenesis and tumor growth? | SREBP1 knockout cancer cell lines and xenografts |
| How does PPARγ T166 phosphorylation affect macrophage lipid synthesis? | PPARγ T166A knock-in mice |
| What is the role of ATF3 in hepatic macrophage metabolic reprogramming? | Atf3 knockout mice fed a MASH-inducing diet |
| Does CD36 promote de novo lipogenesis via INSIG2? | CD36 overexpression and INSIG2 knockdown in hepatocytes |
| Can USP22 inhibition reduce lipid accumulation in HCC? | USP22 knockout HCC cells and mouse models |
| How does GLP-1 from intestinal L-cells regulate hepatic lipid metabolism? | Intestinal L-cell-specific knockout of mechanoreceptors |
How to Study the regulation of lipid biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify lipogenic genes regulated by SREBP1 or PPARγ |
| ChIP-seq | Transcription factor binding sites | Map SREBP1 and PPARγ occupancy on lipogenic promoters |
| Lipidomics (LC-MS) | Lipid species abundance and composition | Quantify de novo lipogenesis in cells and tissues |
| Stable isotope tracing | Metabolic flux through lipogenic pathways | Measure newly synthesized fatty acids |
| CRISPR knockout screens | Gene function on lipid accumulation | Discover novel regulators of ferroptosis resistance |
| BODIPY staining | Cellular lipid droplet content | Assess lipid synthesis in response to genetic perturbations |
| Western blot | Protein expression and post-translational modifications | Detect SREBP1 processing and PPARγ phosphorylation |
| Luciferase reporter assay | Transcriptional activity of lipogenic promoters | Measure SREBP1 or PPARγ activation |
Transcriptomic and Epigenomic Profiling
RNA-seq and ChIP-seq are used to identify genes and transcription factor binding sites regulated during lipid biosynthesis. For example, SREBP1 and PPARγ target genes can be mapped by ChIP-seq in response to metabolic stimuli. ATF3-mediated reprogramming in macrophages was elucidated using RNA-seq.
Lipidomics and Metabolic Flux Analysis
Mass spectrometry-based lipidomics quantifies lipid species and fluxes to assess de novo lipogenesis. Stable isotope tracing with 13C-acetate or 13C-glucose measures newly synthesized fatty acids. These methods are critical for validating the impact of genetic perturbations on lipid biosynthesis.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout or activation screens can identify novel regulators of lipid biosynthetic process. For instance, screens for ferroptosis resistance have uncovered SREBP-mediated lipogenesis. Such screens enable unbiased discovery of genes modulating lipid accumulation.
Imaging and Reporter Assays
Fluorescent lipid dyes (e.g., BODIPY) and luciferase reporters driven by lipogenic promoters allow visualization and quantification of lipid synthesis in live cells. These assays are used to study PPARγ and SREBP1 activity.
How CRISPR Can Be Used to Study GO:0046890 regulation of lipid biosynthetic process
Knockout
CRISPR knockout of key regulators such as SREBP1, PPARγ, or ATF3 enables loss-of-function studies to determine their causal role in lipid biosynthesis. For example, SREBP1 knockout reduces lipogenesis and sensitizes cancer cells to ferroptosis. Liver-specific Atf3 knockout mice reveal its role in MASH.
Point Mutation
Point mutations can mimic or abolish post-translational modifications. The PPARγ T166A knock-in mouse model prevents phosphorylation at T166, leading to enhanced lipid synthesis and improved macrophage reparative function. Such models are invaluable for dissecting signaling events.
Knock-in
Knock-in of tagged or reporter alleles allows tracking of lipogenic proteins in vivo. For instance, knocking in a fluorescent tag on SREBP1 enables live-cell imaging of its nuclear translocation. This approach provides spatial and temporal insights into lipid biosynthesis regulation.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of lipogenic genes such as CD36 or USP22 can drive lipid accumulation. CD36 overexpression in hepatocytes promotes de novo lipogenesis via INSIG2-dependent SREBP1 processing. USP22 overexpression stabilizes PPARγ and enhances lipidome accumulation in HCC.
How EDITGENE Supports regulation of lipid biosynthetic process Research
Researchers studying regulation of lipid biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in lipid accumulation, metabolic reprogramming, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery, from gene knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for regulation of lipid biosynthetic process research.
Frequently Asked Questions About regulation of lipid biosynthetic process
What is GO:0046890 regulation of lipid biosynthetic process?
GO:0046890 is a Gene Ontology biological process term defined as any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids.
What genes are involved in regulation of lipid biosynthetic process?
Key genes include SREBP1, PPARγ, ATF3, CD36, INSIG2, USP22, and components of the PI3K-AKT-mTOR pathway.
How does SREBP1 regulate lipid biosynthesis?
SREBP1 is a transcription factor that activates genes encoding lipogenic enzymes; its processing and nuclear translocation are regulated by INSIG2 and mTOR signaling.
What diseases are associated with dysregulation of lipid biosynthesis?
Dysregulation is linked to metabolic dysfunction-associated steatohepatitis (MASH), hepatocellular carcinoma, ferroptosis resistance, obesity, and type 2 diabetes.
How can CRISPR be used to study regulation of lipid biosynthetic process?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of lipogenic genes to study their causal roles in lipid accumulation and disease.
What is the role of PPARγ in lipid biosynthesis?
PPARγ is a nuclear receptor that promotes lipid synthesis and storage; its dephosphorylation at T166 triggers lipid synthesis in macrophages during tissue repair.
How does CD36 promote de novo lipogenesis?
CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing, enhancing fatty acid synthesis.
What experimental models are used to study lipid biosynthesis regulation?
Common models include liver-specific knockout mice, point mutation knock-in mice, and cell lines with CRISPR-mediated gene edits.
What methods measure lipid biosynthesis?
Methods include RNA-seq, ChIP-seq, lipidomics, stable isotope tracing, BODIPY staining, and luciferase reporter assays.
How does ATF3 regulate lipid metabolism in MASH?
ATF3 mediates metabolic reprogramming in hepatic macrophages, orchestrating metabolic dysfunction-associated steatohepatitis progression.
Conclusion
The regulation of lipid biosynthetic process (GO:0046890) is a central node in metabolic control, with profound implications for human health and disease. Key transcription factors and signaling pathways integrate nutritional and hormonal signals to balance lipid synthesis, and their dysregulation drives conditions such as MASH, hepatocellular carcinoma, and ferroptosis resistance. Advances in CRISPR-based models and multi-omics technologies are accelerating the discovery of novel regulatory mechanisms. Targeting these pathways holds promise for therapeutic intervention in metabolic and oncological diseases.
References
- 1. Song Z et al.. 2018. Regulation and Metabolic Significance of De Novo Lipogenesis in Adipose Tissues.. Nutrients 10(10) PMID: 30274245
- 2. Hu S et al.. 2024. Atf3-mediated metabolic reprogramming in hepatic macrophage orchestrates metabolic dysfunction-associated steatohepatitis.. Sci Adv 10(30):eado3141 PMID: 39047111
- 3. Yi J et al.. 2020. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis.. Proc Natl Acad Sci U S A 117(49):31189-31197 PMID: 33229547
- 4. Ameer F et al.. 2014. De novo lipogenesis in health and disease.. Metabolism 63(7):895-902 PMID: 24814684
- 5. Zuo S et al.. 2024. Lipid synthesis, triggered by PPARγ T166 dephosphorylation, sustains reparative function of macrophages during tissue repair.. Nat Commun 15(1):7269 PMID: 39179603
- 6. Zeng H et al.. 2022. CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing.. Mol Metab 57:101428 PMID: 34974159
- 7. Ning Z et al.. 2022. USP22 regulates lipidome accumulation by stabilizing PPARγ in hepatocellular carcinoma.. Nat Commun 13(1):2187 PMID: 35449157
- 8. Gao L et al.. 2025. Intestinal L-cell mechanoreception regulates hepatic lipid metabolism through GLP-1.. Sci Adv 11(22):eadv3201 PMID: 40446026
